Table 1 2012 European LeukemiaNet prognostic-risk group based on cytogenetic and molecular profile
From: PIM-1 mRNA expression is a potential prognostic biomarker in acute myeloid leukemia
Prognostic-risk group | Cytogenetic profile alone | Cytogenetic profile and molecular abnormalities |
|---|---|---|
Favorable | t(8:21)(q22; q22) inv(16)(p13; 1q22) t(15;17)(q22; q12) | t(8:21)(q22; q22) with no c-KIT mutation inv(16)(p13; 1q22) t(15;17)(q22; q12) Mutated NPM1 without FLT3-ITD (CN-AML) Mutated biallelic CEBPA (CN-AML) |
Intermediate | CN-AML t(9;11)(p22; q23) Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups | t(8:21)(q22;q22) with mutated c-KIT CN-AML other than those included in the favorable or adverse prognostic group t(9;11)(p22; q23) Cytogenetic abnormalities not included in the favorable or adverse prognostic risk groups |
Adverse | inv(3)(q21q26.2) t(6;9)(p23; q34) 11q abnormalities other than t(9;11) −5 or del(5q) −7 Complex karyotype | TP53 mutation, regardless of cytogenetic profile CN with FLT3-ITD CN with DNMT3A CN with KMT2A-PTD inv(3)(q21q26.2) t(6;9)(p23;q34) 11q abnormalities other than t(9;11) −5 or del(5q) −7 Complex karyotype |